PRESENTATIONS FROM OCULAR MELANOMA CONFERENCES

Medical Presentations:

•  Primary Uveal Melanoma (5 sessions; 85 minutes total):

— "Ocular Surveillance — Tumor Control"

 (Dr. Yehonatan Weinberger; begins at time stamp 0:00)

— "Vision Loss After Radiation Treatment (Radiation Retinopathy)"

(Dr. Arun Singh; begins at time stamp 7:15)

— "DNA Testing: Who, When, Why"

(Meghan DeBenedictis, Certified Genetic Counselor; begins at time stamp 20:15)

— "Systemic Surveillance — How?"

(Dr. John Suh; begins at time stamp 34:45)

— "Panel Q & A" (begins at time stamp 1:01:00)

• Metastatic Uveal Melanoma (4 sessions; 90 minutes total):

— "Liver-Directed Therapies"

(Dr. James Isaacs, begins at time stamp 0:00)

— "Immunotherapies and Targeted Therapies"

(Dr. Lucy Boyce Kennedy; begins at time stamp 19:00)

— "Tebentafusp in Practice"

(Dr. Shaheer Khan; begins at time stamp 54:00)

— "Panel Q & A" (begins at time stamp 1:17:00)

• "Preventing Recurrence in Uveal Melanoma: The Role of Adjuvant Therapies"

(Dr. Shaheer Khan; 35 minutes)

• "Uveal Melanoma: Era of Ocular Clinical Trials"

(Dr. Arun Singh; 20 minutes)

• "Uveal Melanoma: Am I Cured Yet?"

(Dr. Arun Singh; 20 minutes)

• "Under the Microscope: Pathology Diagnosis of Ocular Melanoma"

(Dr. Jennifer Brainard; 45 minutes)

All videotaped presentations from this conference

Medical Presentations:

Day 1 Video —

• Current Approaches to the Management of Metastatic Uveal Melanoma 

(Dr. Marcus Butler; 40:35 timestamp start; 45 minutes)

Day 1 includes other videotaped presentations from this symposium

Day 2 Video — 

• Genomic Testing for Uveal Melanoma

(Katherina Alsina, Ph.D.; 3:30 timestamp start; 20 minutes)

Day 2 includes other videotaped presentations from this symposium

Medical Presentations:

Video 1 - Intro and Sessions 1—3:

(Note: Session range on YouTube is incorrectly labeled 1—4)

• 8:00 AM   Welcome

(Dr. Prithvi Mruthyunjaya)

• 8:05 AM   Innovation barriers in ocular oncology

(Dr. Daniel Gombos)

Session 1: What’s in a Picture: Advanced Imaging in Ocular Oncology

• 8:20 AM   Prediction of metastatic risk from fundus photography alone

(Dr. Jared Sokol)

• 8:30 AM   Machine learning analysis of uveal melanoma imaging

(Dr. Michael Heiferman)

• 8:40 AM   AI in ocular oncology for melanocytic lesions

(Dr. Ezekiel Weis)

• 8:45 AM   Ultrawide field OCT in imaging intraocular tumors

(Dr. Alison Skalet)

• 8:50 AM   Trans-palpebral illumination for imaging choroidal tumors

(Dr. Michael Heiferman)

• 9:00 AM   Quantitative high-definition microvessel imaging to distinguish choroidal nevus versus melanoma

(Dr. Lauren Dalvin)

• 9:10 AM   Panel Discussion

(Moderators: Dr. Prithvi Mruthyunjaya and Dr. Jens Killgard)

Session 2: Retinoblastoma 9:30 — 10:30

Session 3: Everyday Problems, New Solutions

• 10:50 AM   How will we use the new COOG2 outcome data?

(Dr. Prithvi Mruthyunjaya)

• 11:00 AM   Iris melanoma: Predictive analysis

(Dr. Arun Singh)

• 11:10 AM   Plaque brachytherapy for conjunctival tumors

(Dr. Hakan Demirci)

• 11:20 AM   Ocular outcomes from systemic therapy for von Hippel-Lindau disease

(Dr. Brian Marr)

• 11:30 AM   Melanoma in situ and squamous cell carcinoma: New potential treatment

(Dr. Randy Christopher Bowen)

• 11:40 AM   Panel Discussion

(Moderators: Dr. Hakan Demirci and Dr. Miguel Materin)

Video 2 - Sessions 4—8:

(Note: Session range on YouTube is incorrectly labeled 5—8)

Session 4: Fluid Is the Fashion (No Longer Tissue Is the Issue)

• 12:00 PM   Proteomics of the tumor mesoenvironment in uveal melanoma

(Dr. Vinit Mahajan)

• 12:10 PM   Aqueous Humor Proteomics for melanoma: A new companion diagnostic

(Dr. Jesse Berry)

• 12:20 PM   The living library for uveal melanoma: Multiomics characterization and utility in drug screening

(Dr. Lauren Dalvin)

• 12:30 PM   Panel Discussion

(Moderators: Dr. Vinit Mahajan and Dr. Jessie Berry)

Session 5: Is Less Really More?: Redirecting Local Treatments in Uveal Melanoma

• 1:45 PM   Ocular radiation dose reduction and vision outcomes

(Dr. Brian Marr)

• 1:55 PM   Dose reduction for radiation therapy in uveal melanoma: Are we ready for a clinical trial?

(Dr. Miguel Materin)

• 2:05 PM   Bel-sar phase 3 and beyond

(Dr. Ivana Kim)

• 2:15 PM   Early biopsy and treatment/observation decision analysis

(Dr. Ezekiel Weis)

• 2:25 PM   Panel Discussion

(Moderators: Dr. Lauren Dalvin and Dr. Arun Singh)

Session 6: Keynote Address

• 2:45 PM   Optimizing prognostication in uveal melanoma

(Dr. Jens Folke Kiilgaard)

• 3:00 PM   Question and Answer Session

Session 7: Progress in Systemic Disease

• 3:05 PM   Current standards in metastatic uveal melanoma

(Dr. Kevin Kim)

• 3:15 PM   Liver directed therapy for metastatic melanoma

(Dr. Sunil Reddy)

• 3:25 PM   Neo-adjuvant therapy for uveal melanoma

(Dr. Pauline Funchain)

• 3:35 PM   Current states of clinical investigation

(Dr. Allison Betof-Warner)

• 3:45 PM   BAP1 tumor predisposition syndrome

(Dr. Colleen Cebulla)

• 3:55 PM   Current status of ctDNA assays for uveal melanoma

(Dr. Ivana Kim)

• 4:05 PM   Panel Discussion

(Moderators: Dr. Allison Betof-Warner and Dr. Ezekiel Weis)

Session 8: Challenging Cases in Ocular Oncology

• 4:35 PM   Panel Discussion: Challenging Cases

Medical Presentations:

• Understanding Clinical Drug Trials: A Doctor’s Perspective for Uveal Melanoma Patients

(Dr. Meredith McKean, Dr. Justin Moser, and Dr. Inderjit Mehmi; 30 minutes)

• Histotripsy and Hepzato: The Future of Liver Cancer Treatment for Uveal Melanoma Metastases

(Dr. Matt Hadfield, Dr. Jason Low, Dr. Vincent Ma, and Dr. Justin Moser; 30 minutes)

• Genetic Metastatic Testing in Uveal Melanoma: Advancements & Challenges

(Dr. Matt Hadfield, Dr. Justin Moser, and Dr. Peaches Ulrich; 40 minutes)

• Understanding Prosthetic Eye Side Effects After Enucleation for Ocular Melanoma

(Dr. Lisa Mihora and Ocularist Starla Allen; 45 minutes)

• "Cancer Detection: The Future of Liquid Biopsies in Uveal Melanoma"

(Dr. Vincent Ma; 45 minutes)

Medical Presentations:

• Post-Radiotherapy Eye Monitoring of Ocular Melanoma Patients: Why It Matters and Managing Complications

(Dr. Guy Negretti; 25 minutes)

• Building the Digital Database & Advancing Uveal Melanoma Research

(Dr. Helen Kalirai; 30 minutes)

• 1) How to Identify an Expert in Uveal Melanoma and 2) The Role of Next Generation Sequencing in Uveal Melanoma

(Professor Paul Nathan; 35 minutes)

• Conjunctival Melanoma and its Precursor Lesions

(Dr. Yamini Krishna; 20 minutes)

• An Update on Clinical Trials for Uveal Melanoma in the UK

(Dr Heather Shaw; 30 minutes)

• Why Me?, Why is My Treatment and Followup Different Than Other Patients?, and Other Popular Questions

(Dr. Hibba Quhill; 30 minutes)

All videotaped presentations from this conference

Medical Presentations:

Morning Video (Part One)

• Uveal Melanoma Basic Science Research

(Andrew Aplin, PhD; 14:20 time stamp; 30 minutes)

• Current Management of Uveal Melanoma

(Dr. Sara Lally; 47:00 time stamp; 45 minutes)

Morning Video (Part Two)

• Risk Assessment and Follow-Up of Uveal Melanoma

(Dr. Rino Seedor; 0:00 time stamp; 15 minutes)

• Neo-Adjuvant and Adjuvant Treatment for High-Risk Primary Uveal Melanoma

(Dr. Rino Seedor; 21:00 time stamp; 20 minutes)

• Systemic Treatments for Metastatic Uveal Melanoma

(Dr. Marlana Orloff; 43:00 time stamp; 30 minutes)

• Multidisciplinary Care, Early Diagnosis & Imaging, and the Rationale for Liver-Directed Treatments for Metastatic Uveal Melanoma

(Dr. Robert Adamo; 1:14:00 time stamp; 25 minutes)

• Immunoembolization and Percutaneous Hepatic Perfusion as Treatment for Metastatic Uveal Melanoma

(Dr. David Eschelman; 1:39:00 time stamp; 20 minutes)

• Radioembolization & Chemoembolization of Uveal Melanoma Hepatic Metastases

(Dr. Carin Gonsalves; 2:00:00 time stamp; 25 minutes)

• The Role of Radiation for Metastatic Uveal Melanoma

(Dr. Pramila Rani Anne; 2:24:00 time stamp; 15 minutes)

Afternoon Video (Part Three)

Presentations from non-profit OM patient organizations about their activities and services are posted on EyeMelanoma.org's Organizations webpage, This video does not contain medical presentations.]

Afternoon Video (Part Four)

• Participating in Ocular Melanoma Clinical Trials [the process plus Q&A]

(Melanoma Research Team Nurse Manager Tina Savio, Assistant Director for Research Operations Katherine Senter, and Dr. Takami Sato; 0:00 time stamp; 60 minutes)

Medical Presentations:

Video 1:

• Moving Towards Cure: A New Chapter for Patients with Uveal Melanoma

(Dr. Richard Carvajal; link preset at 3:45 time stamp; 30 minutes)

Video 2:

• Update on Uveal Melanoma Registries

(Prof. Anthony Joshua; link preset at 0:40 time stamp; 15 minutes)

• IDEAYA Biosciences: Darovasertib Clinical Development for Ocular Melanoma

(Dr. Darrin Beaupre; link preset at 30:29 time stamp; 10 minutes)

Video 3:

• Tebentafusp – What You Need to Know as an Ocular Melanoma Patient

(Prof. Anthony Joshua; link preset at 0:00 time stamp; 20 minutes)

• Targeting GNAQ and GNA11 in Uveal Melanoma

(Assoc. Prof. Matteo Carlino; link preset at 18:52 time stamp; 15 minutes)

Video 4:

• Uveal Melanoma Testing: Options, Interpretation, and Access Pathways

(Prof. Svetlana Cherepanoff; link preset at 0:00 time stamp; 15 minutes)

• Circulating Tumour DNA as a Biomarker in Uveal Melanoma

(Dr. Aaron Beasley; link preset at 15:44 time stamp; 10 minutes)

Video 5:

• How We Work Up Uveal Melanoma: An Ophthalmologist’s Perspective for Patients

(Dr. Tim Isaacs; link preset at 0:00 time stamp; 20 minutes)

• Artificial Eyes in Rehabilitation of Ocular Melanoma Patients

(Ocularist Jenny Geelen; link preset at 22:30 time stamp; 20 minutes)

Video 6:

• Advances in Radiation Treatment of Uveal Melanoma — Australia's New South Wales Experience

(Dr. Wenchang Wong; link preset at 14:15 time stamp; 20 minutes)

Video 7:

• FOCUS Clinical Trial (Percutaneous Hepatic Perfusion): The End of the Beginning for Liver Directed Therapy in Metastatic Uveal Melanoma

(Dr. Joseph Sacco; link preset at 0:00 time stamp; 30 minutes) 

All videotaped presentations from this conference

The time stamp info below shows where you will find the specific presentation within the video.

Medical Presentations:

Track 1 – Morning Video

• Ocular Melanoma: Diagnosis, Biopsies, and Proton Irradiation

(Dr. Frances Wu; 1:20:00 time stamp; 20 minutes)

• Plaque Brachytherapy and Gamma Knife for Ocular Melanoma Patients

(Dr. Shilpa Desai; 1:44:00 time stamp; 15 minutes)

• What to Expect After Radiation for Uveal Melanoma

(Dr. Ivana Kim; 1:58:00 time stamp; 40 minutes)

• Ocular Melanoma Surveillance and Adjuvant Treatment

(Dr. Ryan Sullivan; 2:37:00 time stamp; 45 minutes)

Track 1 – Afternoon Video

• Overview of Metastatic Treatment Approaches in Uveal Melanoma

(Dr. Kamaneh Montazeri; 3:00 time stamp; 25 minutes)

• Tebentafusp in Practice for Ocular Melanoma Patients

(Dr. Ryan Sullivan; 30:29 time stamp; 35 minutes)

• Liver-Directed Therapies for Ocular Melanoma Patients

(Dr. Eric Wehrenberg-Klee; 1:06:00 time stamp; 25 minutes)

• Targeted Systemic Therapies for Uveal Melanoma

(Dr. Rizwan Haq; 1:33:00 time stamp; 25 minutes)

• Immunotherapies for Metastatic Uveal Melanoma

(Dr. Elizabeth Buchbinder; 1:59:00 time stamp; 20 minutes)

Track 2 – Morning Video

• Changes in Sexual Health During and After Ocular Melanoma Cancer Treatment

(Cristina Pozo-Kaderman, PhD; 22:00 time stamp; 40 minutes)

Track 2 – Afternoon Video

• Oncology Nutrition Fact Versus Fiction

(Christina Conte, Registered Dietician; 1:22:00 time stamp; 60 minutes)

Conference's Science Sunday Video 

• The Potential for Circulating Biomarkers in Uveal Melanoma

(Dr. Ryan Sullivan; 57:00 time stamp; 35 minutes)

• Liver Metastases in Ocular Melanoma: Some New Research That I Am Excited About

(Dr. Rizwan Haq; 1:35:00 time stamp; 35 minutes)

Medical Presentations:

Video — All Sessions

Sessions are approximately 15 minutes each. Panel discussions at end of sessions. Presentations relating to Ocular Melanoma are noted below. 

Session 1: Metastatic Uveal Melanoma: Adjuvant, Neoadjuvant, and Active Disease (Start 0:00 Through Time Stamp 1:52:30)

• Impact of PRAME Status on Gene Expression Profile to Predict Metastasis in Uveal Melanoma: Interim Analysis of the Collaborative Ocular Oncology Group Study Number 2 (COOG2)  (Dr. Prithvi Mruthyunjaya)

• Unraveling Cellular Diversity: A Path to Understanding Uveal Melanoma Progression  (Dr. Mathieu Bakhoum)

• Circulating Neoplastic-Immune Hybrid Cells Predict Survival in Uveal Melanoma  (Dr. Alison Skalet)

• Systemic Therapy for Metastatic Uveal Melanoma  (Dr. Kevin Kim)

• Liver-Directed Therapies and Beyond (Dr. Sunil Reddy)

• Past, Present, and Future of Adjuvant Therapy for High-Risk Uveal Melanoma

(Dr. Jose Lutzky)

Session 2: Biomarkers and Diagnostics (Time Stamp 1:52:30 Through Time Stamp 3:06:30)

- It's in the Liquid: How Ancillary Studies in Clinical Trials Will Cure Eye Cancer  (Dr. Dan Gombos)

• Proteomic Analysis of Aqueous Humor in Uveal Melanoma  (Dr. Jesse Berry)

• Liquid Biopsy of Anterior Chamber Fluid in Uveal Melanoma  

(Dr. Vinit Mahajan)

Session 3: Radiation Therapy: Alternatives and Risk Mitigation (Time Stamp 3:06:30 Through 4:22:30)

• Y90 Radiation Therapy: New Frontiers  (Dr. Miquel Materin)

• Management of Exudative Retinal Detachment After Radiation for Choroidal Melanoma  (Dr. Ivana Kim)

• Image-Guided Proton Beam Treatment for Uveal Melanoma  (Dr. Andrew Stacey)

• Radiation Retinopathy: New Strategies  (Dr. Thomas Aaberg, Jr.)

• Radiation-Sparing Local Therapy for Intraocular Metastatic Tumors  

(Dr. Hakan Demirci)

Session 4: Innovations in Pediatric Ocular Oncology (Time Stamp 4:22:30 Through 6:28:00)

• 3D Printing in Ocular Oncology for Ocular Prosthetics  (Dr. Mandeep Sagoo)

Session 5: New Therapeutics and New Toxicities (Time Stamp 6:28:00 Through 7:11:00)

• Outcomes After Proton Irradiation in a Bel Sar Eligible Population  

(Dr. Ivana Kim)

• Immunotherapy for Conjunctival Tumors: A Conservative Approach to Advanced Tumors  (Dr. Hakan Demirci)

Medical Presentations:

• A Look at the UK Uveal Melanoma Guidelines and Ocular Melanoma

Treatments

(Dr. Matthew Wheater; 40 minutes)

• Can Precision Medicine Identify New Opportunities in Ocular Melanoma?

(Dr. Tim Crook; 30 minutes)

• Latest Ocular Melanoma Research Developments and Clinical Trials

(Professor Jeff Evans; 30 minutes)

• What Are Ocular Melanoma Clinical Trials and Why Are They So Important?

(Dr. Archana Bansal; 20 minutes)

• What Is ctDNA and Can It Help Us Start Ocular Melanoma Treatment Early

(Professor Mark Middleton; 40 minutes)

All videotaped presentations from this conference

Medical Presentations:

• Biology of Cancer and Uveal Melanoma

(Lucinda Innes, PhD; Dr. Andrew Stacey; and Dr. Dennis Stacey; 55 minutes)

• Integrative Medicine and Ocular Melanoma

(Dr. Blake Langley; 60 minutes)

• Ocular Melanoma Metastatic Disease 101

(Dr. Julia Brechbiel, Dr. Evan Hall, Lucinda Innes, PhD student; 85 minutes)

• Ocular Prosthetics 101: Design and Care

(Ocularists Todd and Tawnya Cranmore; 65 minutes)

• Ocular Melanoma Treatments and Side Effects

— How to Choose a Treatment  (Dr. Elaine Binkley) 

— Dry Eye Disease After Radiation  (Dr. Minh Nguyen)

— A Brief Overview of Eye Removal Surgery  (Dr. Andrew Stacey)

(total 45 minutes) 

• Palliative Care and Hospice Care in Ocular Melanoma — When to Call Who?

(Dr. Ted Dropcho; 55 minutes)

• Radiation Basics for Ocular Melanoma

— Radiation Retinopathy  (Dr. Chris Bowen)

— Radiation: What Is It and How Does It Work  (Dr. Jonathan Chen)

(total 60 minutes)  

• Research Does Not Equal a Cure — What Brings an Ocular Melanoma Drug to Market?

(Lucinda Innes, PhD; Dr. Steven Katz; Christian Wade, PhD; and patient Kevin; 60 minutes)

• Your Prognosis at Ocular Melanoma Diagnosis

(Dr. Shailender Bhatia, Dr. Julia Brechbiel, and Dr. Andrew Stacey; 60 minutes)

All videotaped presentations from this conference

Medical Presentations:

Video 1

• Uveal Melanoma: Where We Are and Where We Are Going

(Dr. Marlana Orloff; 45 minutes)

Video 2

• Development of the Ocular Oncology Clinical Nurse Consultant Role: Impact on Ocular Melanoma Patient Care

(Clinical Nurse Peta Holly; 10 minutes)

Video 3

• Determinants of PKC Inhibitor Response in Uveal Melanoma

(Professor Helen Rizos; 15 minutes)

• Drug Discovery and Development in Human Uveal Melanoma

(Associate Professor Fanfan Zhou; 15 minutes)

• Improving Plaque Brachytherapy for Uveal Melanoma

(Honorary Researcher Jeremy Flanagan; 15 minutes)

• Q&A  

(All Video 3 Presenters; 5 minutes)

Video 4

• How Do Optometrists Manage Choroidal Melanocytic Lesions?

(Associate Professor Michelle Madigan; 15 minutes)

• Uveal Melanoma Tumour Biopsy: South Australia Experience

(Dr. David Sia; 10 minutes)

• Uveal Melanomas: South Australia Pathology Experience

(Dr. Amardeep Gilhotra; 10 minutes)

• An Update on Proton Therapy for Ocular Melanoma in Australia and Clinical Application  

(Associate Professor Peter Gorayski; 20 minutes)

• The Incidence and Mortality of Conjunctival Melanoma in Australia

(Dr. Aaron Beasley; 15 minutes)

• Q&A  

(All Video 4 Presenters; 10 minutes)

Video 5

• Locoregional Therapies for Metastatic Uveal Melanoma

(Professor Roger Olofsson Bagge; 30 minutes)

• Genomics and Prognostication in Uveal Melanoma

(Dr. Emine Kilic; 35 minutes)

• Q&A  

(All Video 5 Presenters; 15 minutes)